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RESEARCH ARTICLE Open Access
5-azacytidine induces transcriptome
changes in Escherichia coli via DNA
methylation-dependent and DNA
methylation-independent mechanisms
Kevin T. Militello1*, Robert D. Simon1, Alexandra H. Mandarano1,2, Anthony DiNatale1, Stacy M. Hennick1,
Justine C. Lazatin1 and Sarah Cantatore1
Abstract
Background: Escherichia coli K-12 strains contain DNA cytosine methyltransferase (Dcm), which generates
5-methylcytosine at 5′CCWGG3′ sites. Although the role of 5-methylcytosine in eukaryotic gene expression is
relatively well described, the role of 5-methylcytosine in bacterial gene expression is largely unknown.
Results: To identify genes that are controlled by 5-methylcytosine in E. coli, we compared the transcriptomes of
cells grown in the absence and presence of the DNA methylation inhibitor 5-azacytidine. We observed expression
changes for 63 genes. The majority of the gene expression changes occurred at early stationary phase and were
up-regulations. To identify gene expression changes due to a loss of DNA methylation, we compared the
expression of selected genes in a wild-type and dcm knockout strain via reverse transcription quantitative PCR.
Conclusions: Our data indicate that 5-azacytidine can influence gene expression by at least two distinct
mechanisms: DNA methylation loss and a mechanism that is independent of DNA methylation loss. In addition, we
have identified new targets of 5-methylcytosine-mediated regulation of gene expression. In summary, our data
indicate that 5-azacytidine impacts the composition of the bacterial transcriptome, and the primary effect is
increased gene expression at early stationary phase.
Keywords: Stationary phase, 5-azacytidine, DNA methylation inhibitor, DNA methylation, 5-methylcytosine, Dcm,
RpoS, Escherichia coli, Sodium bisulfite sequencing, DNA microarray
Background
The modified DNA base 5-methylcytosine (5-MeC) plays
an important role in transcriptional regulation in higher
eukaryotes. The presence of 5-MeC in eukaryotic pro-
moters and CpG islands is generally repressive for tran-
scription, whereas 5-MeC in gene bodies is positively
correlated with transcription [1]. Bacteria, such as E.
coli, contain 5-MeC [2]. In E. coli K-12 strains, the only
known cytosine-5 DNA methyltransferase is DNA cyto-
sine methyltransferase (Dcm) [3, 4]. Dcm methylates the
second cytosine in 5′CCWGG3′ sequences [3]. The dcm
gene is in an operon with the vsr gene which codes for a
protein that repairs T:G mismatches caused by deamin-
ation of 5-MeC [5–7]. The original function elucidated
for Dcm was in restriction enzyme biology where Dcm
promotes the loss of plasmids containing the EcoRII re-
striction enzyme gene (which cleaves 5′CCWGG3′ sites)
and protects cells from post-segregational killing by the
EcoRII restriction enzyme [8, 9]. In addition, Dcm pro-
tects phage lambda against DNA cleavage when EcoRII
is introduced into the cell [10]. However, Dcm is a soli-
tary methyltransferase without a cognate restriction en-
zyme in K-12 cells. Other roles for Dcm are certainly
possible.
Based on the important role of 5-MeC in eukaryotic
transcription and the fact that there is little known about
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the relationship between 5-MeC and gene expression in
bacteria, Dcm has been recently evaluated for an impact
on the composition of the E. coli transcriptome. Our
group has demonstrated that two ribosomal protein
genes and the drug resistance transporter gene sugE are
upregulated in the absence of the dcm gene at early sta-
tionary phase via reverse-transcription quantitative PCR
(RT-qPCR) [11, 12]. Kahramanoglou et al. demonstrated
that there are gene expression changes in dcm knockout
cells using DNA microarrays, and most changes are at
stationary phase [13]. Taken together, these data suggest
that Dcm influences the transcriptome. As the only
known function of Dcm is cytosine DNA methylation,
the simplest model is that Dcm mediates gene expres-
sion changes via the generation of 5-MeC. It is note-
worthy that some DNA methyltransferases can
methylate tRNA and influence gene expression via a
DNA-methylation independent mechanism [14–16].
In order to test the model that Dcm-mediated cytosine
DNA methylation directly influences gene expression in
E. coli and identify new genes impacted by DNA methy-
lation, we analyzed the E. coli transcriptome in the ab-
sence and presence of 5-azacytidine (5-azaC) treatment.
5-azaC is a nucleoside analog that is used clinically to
treat myelodysplastic syndromes [17]. 5-azaC is phos-
phorylated upon cell entry and incorporated into both
RNA and DNA [18, 19]. When 5-azaC is incorporated
into DNA, cytosine-5 DNA methyltransferases become
covalently trapped on the DNA and are degraded, and
this limits the amount of enzyme available for the gener-
ation of 5-MeC [18, 19]. Thus, 5-azaC is a cytosine
DNA methylation inhibitor. It is important to note that
5-azaC has effects on the cell beyond blocking DNA
methylation. For example, 5-azaC can induce the SOS
response [20, 21], induce DNA mutations [22], block
translation [23], and block RNA methylation [24]. Thus,
the physiology of 5-azaC treated cells is not identical to
cells lacking cytosine DNA methyltransferases. Although
5-azaC has been routinely used to demethylate DNA in
a variety of eukaryotes to assess the consequences of
cytosine DNA methylation loss [25, 26], this is the first
report of the response of the entire transcriptome to 5-
azaC in a bacterial organism.
Results
Effects of 5-azaC on global DNA methylation levels
First, we determined the concentration dependence of
DNA methylation inhibition by 5-azaC using digestion
of DNA with the restriction enzyme isoschizomers BstNI
and PspGI (Fig. 1). Both enzymes cut DNA at Dcm rec-
ognition sites (5′CCWGG3′), but PspGI is blocked by
Dcm-mediated methylation of the second cytosine. In
the absence of 5-azaC, DNA from early stationary phase
cells was largely resistant to PspGI indicating that the
DNA is heavily methylated at this stage. At early loga-
rithmic stage, DNA was slightly sensitive to PspGI, indi-
cating that most but not all 5′CCWGG3′ sites are
methylated. These data are consistent with our current
Fig. 1 The effect of 5-azaC on global DNA methylation levels in Escherichia coli. E. coli wild-type strain BW25113 was grown in LB at 37 °C in the
absence of 5-azaC, the presence of 0.5 μg/mL 5-azaC, 5 μg/mL 5-azaC, and 50 μg/mL 5-azaC. At two hours (logarithmic phase, L) and eight hours (early
stationary phase, S), genomic DNA was isolated. DNA was incubated in the absence of restriction enzyme, presence of BstNI (B) (not blocked by Dcm
methylation), or presence of PspGI (P) (blocked by Dcm methylation). DNA samples were analyzed by agarose gel electrophoresis and ethidium
bromide staining
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results (Fig. 3) indicating that there is 100 % methylation
of a single osmE 5′CCWGG3′ site analyzed by sodium
bisulfite sequencing from early stationary phase DNA
and 93.3 % methylation of a single osmE 5′CCWGG3′
site analyzed by sodium bisulfite sequencing from loga-
rithmic phase DNA. The data are also consistent with
previously published results indicating stationary phase
DNA is heavily methylated, whereas logarithmic phase
DNA is methylated but has some unmethylated sites
[13, 27]. It is currently unclear if the lack of 100 %
methylation at logarithmic phase is due to active DNA
replication where newly synthesized DNA is unmethy-
lated or regulation of DNA methylation. When DNA
was isolated from cells incubated in the presence of 5-
azaC, the DNA was more sensitive to digestion with
PspGI, indicating 5-azaC inhibits DNA methylation at
all concentrations used at both phases. There was an in-
crease in PspGI sensitivity as the concentration moved
from 0.5 μg/mL 5-azaC to 5 μg/mL 5-azaC, especially in
early stationary phase DNA.
Effects of 5-azaC on bacterial growth
We conducted experiments to determine the effects of
5-azaC on the kinetics of E. coli growth (Fig. 2). Bacterial
cells were grown in the absence of 5-azaC and three
concentrations of the drug as described previously.
There was little effect of 5-azaC on bacterial growth for
the first few hours. At two hours, which represents loga-
rithmic phase and one time point for the DNA micro-
array analysis, ANOVA indicated that there is not a
statistically significant difference in A600 readings be-
tween the four cultures (p = 8.3E-2). This is likely due to
the fact that 5-azaC has to be transported into the cells,
phosphorylated, and incorporated into nucleic acids be-
fore it is active. After 8 h of growth in 5-azaC (early sta-
tionary phase), ANOVA indicated there was a
statistically significant difference in A600 readings (p =
9.9E-5). Post hoc analysis indicated that there was no
difference in A600 readings between untreated cultures
and cultures grown in 0.5 μg/mL 5-azaC (p = 1.4E-1).
However, there was a statistically significant difference
between untreated cultures and cultures grown in 5 μg/
mL 5-azaC (p = 4.7E-3) and 50 μg/mL 5-azaC (p = 7.6E-
5). In summary, the data are consistent with previous ex-
periments indicating that high concentrations of 5-azaC
can inhibit bacterial growth [28–30]. Based on the PspGI
digestion data and the growth curve data above, we
chose 5 μg/mL as our working concentration of 5-azaC.
At 5 μg/mL, there is an obvious reduction of DNA
methylation, and the reduction is greater than that
Fig. 2 The effect of 5-azaC on Escherichia coli growth in liquid media. E. coli wild-type strain BW25113 was grown in LB at 37 °C in the absence of
5-azaC (black squares), the presence of 0.5 μg/mL 5-azaC (red circles), 5 μg/mL 5-azaC (green triangles) and 50 μg/mL 5-azaC (blue diamonds) for eight
hours. At every hour, each culture was analyzed by spectrophotometry at 600 nm. The data are from three biological replicates (n = 3). Error bars
representing standard deviation are not shown to maintain clarity of the four lines. Brackets indicate time points of RNA isolation for microarray
analysis, and data analyzed by ANOVA. The asterisk indicates a p-value of <0.05
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observed using 0.5 μg/mL 5-azaC. With respect to
growth defects, the growth defect with 5 μg/mL 5-azaC
is less than that observed using 50 μg/mL 5-azaC. A se-
vere growth defect could compromise the interpretation
of downstream DNA microarray experiments.
Effects of 5-azaC on site specific methylation
The PspGI assay described above to monitor DNA
methylation is primarily qualitative. To better quantify
the ability of 5-azaC to block DNA methylation in
Escherichia coli, we analyzed the osmE promoter re-
gion for 5-MeC from cells grown in the absence and
presence of 5 μg/mL 5-azaC using sodium bisulfite
sequencing. Treatment of DNA with sodium bisulfite
causes the deamination of cytosines to uracils, but 5-
MeCs are not deaminated and remain as cytosines in
DNA sequencing reactions [31]. OsmE was chosen as
it contains one 5′CCWGG3′ site in its promoter. The
sodium bisulfite sequencing data are shown in Fig. 3.
At the second cytosine in the single 5′CCWGG3′ site
in the DNA analyzed, 93.3 % of the logarithmic phase
cytosines and 100 % of the early stationary phase cy-
tosines were resistant to bisulfite conversion. At the
remaining 34 non-5′CCWGG3′ sites, only 3.3 % of
the logarithmic phase cytosines and 2.6 % of the early
stationary phase cytosines were resistant to bisulfite
conversion. The data are consistent with the model
that Dcm methylates 5′CCWGG3′ sites. Low levels of
non-5′CCWGG3′ methylation are most easily ex-
plained by a very low level of non-conversion of cyto-
sines to uracil, which is always observed in bisulfite
sequencing reactions. However, it is not possible to
rule out low levels of non-5′CCWGG3′ methylation.
In the presence of 5-azaC, the level of methylation at
the 5′CCWGG3′ site was reduced from 93.3 % to
28.6 % at logarithmic phase and from 100 % to 50 %
at early stationary phase. The potency of 5-azaC at
early logarithmic phase is likely due to better incorp-
oration of the drug into DNA during DNA replication
at this stage, yet there is inhibition at early stationary
phase as well. In summary, the data demonstrate that
5 μg/mL 5-azaC blocks, but does not eliminate, DNA
methylation at 5′CCWGG3′ sites in E. coli.
Transcriptome changes in 5-azaC treated cells
We compared E. coli transcriptomes in the absence and
presence of 5-azaC using DNA microarray analysis of
logarithmic phase and early stationary phase RNAs
(Additional files 1 and 2). Overall, we detected six up-
regulated genes and one down-regulated gene at loga-
rithmic phase (Table 1), and 44 up-regulated genes and
12 down-regulated genes at early stationary phase
(Table 2). To confirm the validity of the microarray ex-
periments, we analyzed expression of the recA and rsmI
genes in 5-azaC treated cells via RT-qPCR (Table 3). The
RT-qPCR experiments confirmed the direction of the
changes observed in the microarray experiments; the
RT-qPCR fold-changes were slightly higher.
At logarithmic phase, the most obvious changes are
genes that respond to DNA damage such as recN, dinD,
dinB, and dinG. DAVID analysis indicates that the DNA
repair and SOS response functional categories are over-
represented in this list (Table 4). We used a moderately
stringent cut off for gene expression changes and there
are other up-regulated SOS genes that have a p value
<0.05, but did not make the FDR cutoff. One example is
recA, which was shown to be up-regulated by RT-qPCR
(Table 3). To determine if the gene expression changes
are due to a direct effect of 5-azaC or loss of DNA
methylation, we analyzed expression of recA and rsmI in
a dcm knockout strain. RecA expression did not change
in the dcm knockout strain indicating 5-azaC-dependent
recA gene expression changes are not due to a loss of
DNA methylation. However, expression of rsmI, a 16S
rRNA methyltransferase, was increased in the dcm
knockout strain, indicating rsmI expression is influenced
by Dcm.
We further inspected the data for expression of DNA
repair pathway genes in the presence of 5-azaC. The
need for DNA repair after 5-azaC treatment is predicted
to be due to the formation of DNA-Dcm crosslinks, as
Dcm overexpression strains display increased sensitivity
to 5-azaC induced killing [21, 28, 29, 32]. In addition,
DNA repair may result in synthesis of new unmethylated
DNA and explain methylation-dependent gene expres-
sion changes. At logarithmic phase, there is little evi-
dence for 5-azaC induced expression of the mismatch
repair genes mutS, mutH, and mutL, nucleotide excision
repair pathway genes uvrA, uvrB, and uvrC, and pyrimi-
dine base excision repair genes ung, nth, mug, and mutM
(Table 1). We cannot rule out induction under condi-
tions that were not evaluated. We did observe up-
regulation of one gene that functions in translesion syn-
thesis (dinB). The significance of increased dinB expres-
sion is unclear. Translesion synthesis is not thought to
be required for 5-azaC induced DNA-protein crosslink
repair as translesion mutants do not display increased
sensitivity to the drug [21, 30, 32, 33]. Interestingly,
three of the seven genes in Table 1 have a defined or
predicted role in homologous recombination (recN,
rmuC, dinG). Homologous recombination is thought to
be the main pathway required for repair of 5-azaC in-
duced damage as homologous recombination mutants
are more sensitive to 5-azaC than wild-type strains [21,
28, 30, 32–34]. Thus, our data are consistent with a
model where 5-azaC induced damage is repaired by
homologous recombination, and components of this
pathway are upregulated in 5-azaC treated cells.
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Fig. 3 (See legend on next page.)
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At early stationary phase, there are 56 differentially
expressed genes. Interestingly, the early stationary
phase gene list is completely different from the loga-
rithmic phase list (Tables 1 and 2). DAVID analysis
identified functional categories ribosome and organ-
elle inner membrane as overrepresented in the early
stationary phase list (Table 4). Ribosomal protein
genes have previously been reported as up-regulated
in the dcm knockout strain [12, 13] and the organelle
inner membrane list contains sugE, which has previ-
ously been reported to be up-regulated in the absence
of dcm [11]. To identify new target genes impacted
by cytosine DNA methylation, we analyzed a few tar-
gets in the dcm knockout strain via RT-qPCR
(Table 3). We investigated osmE via RT-qPCR as it
has a 5′CCWGG3′ site in its promoter (Fig. 3). OsmE
expression decreases in the dcm knockout strain at
early stationary phase, indicating Dcm influences
osmE expression. OsmE was also down-regulated in
the dcm knockout strain at stationary phase via RT-
qPCR. Interestingly, osmE is the first example of a
gene that is dependent upon Dcm for maximal ex-
pression. The expression of atpH, a subunit of ATP
synthase, did not change in the dcm knockout
strain, indicating the 5-azaC-dependent gene expres-
sion change is not due to a loss of DNA methyla-
tion. FimA, a fimbria subunit, was upregulated in
the dcm knockout strain indicating control by Dcm.
The expression of the cspB gene, a cold shock pro-
tein, increased in the dcm knockout strain, but not
to the extent observed with 5-azaC treatment. Thus,
cspB may respond to both the loss of DNA methyla-
tion and a 5-azaC-dependent DNA methylation-
independent mechanism.
Discussion
At logarithmic phase, the dcm gene is expressed as de-
tected by microarray analysis and the DNA is methyl-
ated at 5′CCWGG3′ sites (Figs. 1 and 3). Yet there are
very few 5-azaC-induced gene expression changes in the
wild-type strain. The majority of 5-azaC changes are in
DNA repair protein genes and are likely due to DNA
damage and activation of the SOS response rather than
a loss of DNA methylation (Table 4). 5-azaC-dependent
activation of the SOS response has been reported [20,
21], and the pathway promotes survival in the presence
of 5-azaC [20, 21, 28, 30, 32–34]. Although it is possible
that we are missing dcm-dependent changes due to a
moderately stringent statistical cutoff and/or the lack of
100 % methylation inhibition via 5-azaC, a simple model
based on our data and three recent articles is that Dcm
has only a minor effect on the logarithmic stage tran-
scriptome [11–13]. It is noteworthy that the effect of
Dcm on the transcriptome has only been tested under
standard conditions (rich medium, 37 °C, aerobic, la-
boratory strain), and future work will evaluate other
conditions.
At early stationary phase, the dcm gene is expressed as
detected by microarray analysis, the DNA is methylated
at 5′CCWGG3′ sites, and there are numerous 5-azaC-
dependent gene expression changes. Not all of the genes
induced by 5-azaC at stationary phase are predicted to
Table 1 Gene expression changes in logarithmic phase, 5-azacytidine-treated Escherichia coli cells
Gene
ID
Name Description fold change
(log2)
p
b2616 recN Recombination and repair 2.76 2.52E-04
b3645 dinD DNA-damage-inducible protein, function unknown 2.24 2.20E-05
b3146 rsmI 16S rRNA C1402 2′-O-ribose methyltransferase, SAM-dependent 1.82 5.84E-05
b0231 dinB DNA polymerase IV, capable of translesion synthesis; overexpression enhances mutagenesis; mediates
targeted mutagenesis by 4-NQO; intrinsic AP lyase activity
1.52 2.28E-04
b3832 rmuC DNA recombination protein; mutants have elevated recombination at microhomologies 1.30 3.36E-05
b0799 dinG ATP-dependent DNA helicase; putative repair and recombination enzyme, monomeric 1.05 1.74E-04
b2876 yqeC Putative selenium-dependent hydroxylase accessory protein −1.13 7.92E-05
(See figure on previous page.)
Fig. 3 5-azaC reduces cytosine DNA methylation of the osmE promoter in Escherichia coli. E. coli wild-type strain BW25113 was grown in LB at 37 °C in the
absence of 5-azaC and presence of 5 μg/mL 5-azaC. DNA was isolated after two hours (logarithmic phase) and eight hours (early stationary phase). DNA
samples were treated with sodium bisulfite. The osmE locus was amplified by PCR using sodium bisulfite-treated DNA as a template. PCR products were
inserted into the plasmid pGEM-T Easy, and analyzed by Sanger sequencing. a) logarithmic phase DNA in untreated cells, b) logarithmic phase DNA in
5-azaC treated cells, c) early stationary phase DNA in untreated cells, and d) early stationary phase DNA in 5-azaC treated cells. The numbers represent the
position of the cytosines with respect to the transcription start site (+1). The cytosines in the 5′CCWGG3′ site are at positions −13 and −12. Open boxes
represent Cs in the osmE sequence (Ts after bisulfite sequencing), and closed boxes represent 5-MeCs in the osmE sequence (Cs after bisulfite sequencing).
Rows represent different clones. Xs represent ambiguous sequence information
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Table 2 Gene expression changes in early stationary phase, 5-azacytidine-treated Escherichia coli cells
Gene ID Name Description fold-change (log2) p
b1557 cspB Cold shock protein, Qin prophage; cold shock inducible 3.40 7.28E-04
b2699 recA Multifunctional DNA recombination and repair protein; ssDNA-dependent ATPase;
synaptase; ssDNA and dsDNA binding protein forming filaments; ATP-dependent homologous
DNA strand exchanger; recombinase A; LexA autocleavage cofactor
2.53 4.87E-05
b3175 secG SecYEG inner membrane translocon secA-interacting subunit;
preprotein translocase secAYEG subunit
2.43 3.43E-04
b4177 purA Adenylosuccinate synthase, purine synthesis 2.37 6.70E-04
b4314 fimA Fimbrin type 1, major structural subunit; phase variation 2.11 1.33E-03
b3231 rplM 50S ribosomal subunit protein L13; binds Zn(II) 2.00 1.12E-03
b3186 rplU 50S ribosomal subunit protein L21 1.92 5.10E-04
b3230 rpsI 30S ribosomal subunit protein S9 1.77 3.95E-04
b3739 atpI ATP synthase, membrane-bound accessory factor 1.68 7.67E-04
b0406 tgt tRNA-guanine transglycosylase; queuosine biosynthesis; zinc metalloprotein 1.66 1.97E-03
b3735 atpH ATP synthase subunit delta, membrane-bound, F1 sector 1.66 1.70E-03
b4200 rpsF 30S ribosomal subunit protein S6; suppressor of dnaG-Ts 1.64 2.18E-03
b3409 feoB Putative ferrous iron permease with GTP-binding domain 1.62 3.37E-03
b3810 yigA DUF484 family protein, function unknown 1.57 2.66E-03
b0926 ycbK Periplasmic M15A family non-protease, function unknown 1.56 8.53E-04
b0927 ycbL Glyoxalase II homolog, function unknown 1.56 3.57E-03
b3704 rnpA RNase P, C5 protein component; involved in tRNA and 4.5S RNA-processing 1.56 2.51E-03
b3342 rpsL 30S ribosomal subunit protein S12; RNA chaperone 1.54 2.60E-05
b4238 nrdD Ribonucleoside-triphosphate reductase; class III anaerobic ribonucleotide reductase 1.54 1.83E-03
b1147 ymfL Function unknown, e14 prophage 1.53 1.66E-03
b2150 mglB D-galactose-, D-glucose-binding protein, periplasmic;
substrate recognition for transport and chemotaxis; binds calcium
1.45 2.24E-03
b4148 sugE Multidrug efflux pump; overexpression resistance to cetylpyridinium 1.44 1.22E-03
b3983 rplK 50S ribosomal subunit protein L11; kasugamycin sensitivity 1.44 2.33E-03
b0118 acnB Aconitate hydratase 2; aconitase B; 2-methyl-cis-aconitate hydratase; iron-sulfur cluster; monomeric 1.42 1.80E-03
b0407 yajC SecDFyajC membrane secretion complex subunit;
assists the SecYE translocon to interact with SecA and export proteins
1.41 2.23E-03
b3357 crp cAMP-activated global transcription factor; mediator of catabolite repression; CRP; CAP 1.40 1.49E-04
b2796 sdaC L-serine:H+ symport permease, threonine-insensitive 1.40 1.84E-03
b3637 rpmB 50S ribosomal subunit protein L28 1.38 9.87E-05
b3508 yhiD Predicted Mg(2+) transport ATPase, MgtC family, function unknown; inner membrane protein 1.35 2.62E-03
b3339 tufA Translation elongation factor EF-Tu 1; GTP-dependent binding of aa-tRNA to the A-site of ribosomes;
has intrinsic GTPase activity when bound to kirromycin
1.33 3.21E-03
b3985 rplJ 50S ribosomal subunit protein L10; streptomycin resistance 1.30 3.36E-03
b0428 cyoE Cytochrome o oxidase protoheme IX farnesyltransferase subunit 1.26 8.29E-04
b0174 ispU Undecaprenyl pyrophosphate synthase; dimeric 1.22 1.14E-04
b0756 galM Aldose 1-epimerase, type-1 mutarotase; galactose mutarotase; monomeric 1.21 1.92E-03
b0946 zapC FtsZ stabilizer 1.19 1.47E-04
b2279 nuoK NADH:ubiquinone oxidoreductase subunit K, complex I; NADH dehydrogenase I 1.15 2.64E-04
b0388 aroL Shikimate kinase II 1.12 6.85E-04
b4237 nrdG Ribonucleotide reductase activase, generating glycyl radical; contains iron; binds NrdD tightly 1.11 4.09E-04
b4016 aceK Isocitrate dehydrogenase kinase/phosphatase 1.11 1.10E-03
b1847 yebF Extracellular Colicin M immunity family protein; function unknown 1.08 5.59E-04
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be due to a loss of DNA methylation and future work
will elucidate the mechanism of these gene expression
changes not described in this article. A simple model
based on our work and three recent studies is that Dcm
has a significant impact on the early stationary phase
transcriptome [11–13]. The mechanism of Dcm-
dependent control of gene expression is not known and
remains an enigma. Kahramanoglou et al. provided evi-
dence that Dcm controls expression of the stationary
phase specific RNA polymerase subunit rpoS gene and a
loss of Dcm generates an increase in RpoS and RpoS-
dependent gene products [13]. However, we did not
observe up-regulation of rpoS expression in 5-azaC
treated cells or dcm knockout cells via DNA microarrays
and RT-qPCR (Tables 1, 2 and 3). What could explain
the differences in rpoS expression in the absence of the
dcm gene in the two studies? It is possible that genetic
differences between the MG1655 strain used in the Kah-
ramanoglou et al. study and the BW25113 strain used in
this study could explain the differences in rpoS expres-
sion in the absence of dcm. The genome sequence of
BW25113 was released in 2014 [35]. BLASTN searches
using the MG1655 rpoS gene and 1000 basepair up-
stream region as a query indicated the same region is
Table 2 Gene expression changes in early stationary phase, 5-azacytidine-treated Escherichia coli cells (Continued)
b3961 oxyR Oxidative and nitrosative stress transcriptional regulator 1.08 2.03E-03
b0463 acrA AcrAB-TolC multidrug efflux pump; additionally dye, detergent, solvent resistance;
membrane-fusion lipoprotein
1.06 2.36E-04
b3255 accB Acetyl-CoA carboxylase, biotin carboxyl carrier protein; BCCP; homodimeric 1.05 6.41E-04
b0083 ftsL Cell division and growth, membrane protein 1.01 9.70E-04
b1195 ymgE UPF0410 family predicted inner membrane protein; function unknown −1.01 2.15E-03
b0255 insN' Pseudogene reconstruction, fused IS911 transposase AB −1.08 2.42E-04
b4107 yjdN Metalloprotein superfamily protein, function unknown −1.30 4.90E-04
b1223 narK Nitrate/nitrite antiporter; promotes nitrite extrusion and uptake −1.31 3.47E-03
b1739 osmE Osmotically inducible lipoprotein, function unknown −1.46 1.01E-03
b0836 bssR Repressor of biofilm formation by indole transport regulation;
global regulator. e.g. of AI-2 transport and motility genes
−1.52 5.23E-05
b1795 yeaQ UPF0410 family protein, function unknown −1.56 1.65E-03
b2414 cysK Cysteine synthase A, O-acetylserine sulfhydrylase A;
homodimeric; selenate, azaserine, chromate resistance;
alkali-inducible, sulfate starvation-inducible protein SSI5; cysteine desulfhydrase
−1.58 2.86E-03
b0806 mcbA Stimulates colanic acid mucoidy, YhcN family, periplasmic; suppresses biofilm formation;
repressed by McbR
−1.71 5.11E-04
b2425 cysP Thiosulfate-binding protein, periplasmic −1.84 1.90E-04
b0506 allR Repressor for all (allantoin) and gcl (glyoxylate) operons; glyoxylate-inducible −1.93 1.10E-03
b0456 ybaA DUF1428 family protein −1.98 2.30E-03
Table 3 RT-qPCR analysis of gene expression changes in 5-azacytidine treated and dcm knockout Escherichia coli
Gene Phase fc (log2) + aza/-aza (array) fc (log2) + aza/-aza (RT-qPCR) fc (log2) Δdcm/wild-type (RT-qPCR)
recA log 2.96 3.65a 0.68
rsmI log 1.82 3.54b 2.86a
atpH early stationary 1.66 0.64
cspB early stationary 3.40 1.46a
fimA early stationary 2.11 1.46a
osmE early stationary −1.46 −1.79a
recA early stationary 2.53 2.98b 0.98
rpoS early stationary 0.69 0.035 0.17
osmE stationary −3.0a
rpoS stationary −0.15
afc (log2) > or <1 and p < 0.05 in qPCR experiment
bfc (log2) > or <1 and p < 0.005 in qPCR experiment
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100 % identical in BW25113 (data not shown). We also
sequenced the main rpoS promoter responsible for sta-
tionary phase specific expression [36, 37], and there are
no sequence differences between MG1655 and
BW25113 (Additional file 3). We also sequenced four
rpoS transcriptional start sites identified by Mendoza-
Vargas et al. [38], and found no genetic differences be-
tween the two strains (Additional file 3). In summary,
we have no evidence for genetic differences that poten-
tially influence rpoS expression in MG1655 and
BW25113. We certainly cannot rule out genetic changes
outside of the rpoS loci in the two strains, epigenetic dif-
ferences in the two strains, or posttranscriptional regula-
tion of rpoS expression via Dcm.
Therefore, our data are not consistent with a model
of Dcm-mediated regulation via RpoS and we must
consider alternative models. What other molecules
are stationary phase specific that could be effector
molecules? One possibility is small RNAs, as some
small RNAs are up-regulated in E. coli during station-
ary phase [39], and small RNAs are known to guide
DNA methylation in plants [40]. Also, two of the best
described Dcm-influenced genes, sugE and osmE, con-
tain 5′CCWGG′3 sites near the -10 region of the
promoter. Therefore, a model where Dcm directly in-
fluences gene expression by direct methylation of tar-
get genes still must be evaluated. DNA methylation
could influence gene expression via numerous mecha-
nisms including the alteration of DNA structure and
influencing transcription factor binding. With respect
to osmE, Regulon DB indicates the transcription fac-
tors FIS and IHF bind to the osmE promoter, but the
binding sites do not overlap the 5′CCWGG3′ site
[41]. It is important to note that ~11 % of E. coli
promoters contain 5′CCWGG3′ sites [12]. Yet, most
of these genes are not changing in response to DNA
methylation loss, and therefore promoter methylation
is not likely a common mechanism to control gene
expression.
Since we observed gene expression changes in the ab-
sence of Dcm, another question concerns the biological
consequences of the gene expression changes. As the
vast majority of gene expression changes occur at early
stationary phase, it is possible that Dcm has a role in
stationary phase biology. During stationary phase of cells
grown in liquid culture, ~99 % of the cells die within 7–
10 days [42]. Subsequently, cells persist for long periods
of time where waves of mutations can generate cells that
can outcompete their predecessors (growth advantage at
stationary phase, GASP). We are currently working to
determine if Dcm promotes or reduces GASP.
Conclusions
In this report, the E. coli transcriptomes of cells grown
in the absence and presence of the cytosine DNA
methylation inhibitor 5-azaC were compared. 5-azaC
was found to be an effective DNA demethylating agent
in E. coli. 5-azaC induced expression changes in 63 E.
coli genes. The majority of the changes occurred at early
stationary phase and were up-regulations. There are at
least two mechanisms by which 5-azaC can induce gene
expression changes. The first pathway is a DNA
methylation-independent pathway that likely involves a
DNA damage response. The second pathway is a DNA
methylation-dependent pathway which occurs in the ab-
sence of changes in rpoS expression. The precise mech-
anism by which cytosine DNA methylation influences
gene expression will be the focus of future studies.
Methods
Bacterial strains and growth
E. coli K-12 wild-type strain BW25113 and dcm
knockout strain JW1944-2 have been previously de-
scribed [12, 43]. The BW25113 (wild-type strain) geno-
type is F−, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-,
rph-1, Δ(rhaD-rhaB)568, hsdR415. The JW1994-2 (dcm
knockout strain) genotype is F−, Δ(araD-araB)567,
ΔlacZ4787(::rrnB-3), λ-, Δdcm-735::kan, rph-1, Δ(rhaD-
rhaB)568, hsdR415. Cells were grown in LB at 37 °C
with shaking at 250 RPM to logarithmic phase (~2 h,
A600 of ~0.45), early stationary phase (~8 h, A600 of
~2.7), and stationary phase (~24 h, A600 of 3.8). 5-azaC
(Sigma) was dissolved fresh in 1x PBS at 5 mg/ml, steril-
ized by filtration through a 0.22 μM filter, and added to
experimental samples at 0.5–50 μg/mL. The same vol-
ume of 1x PBS was added to control flasks.
DNA methylation analysis via PspGI digestion
DNA was isolated from 2 mL of bacterial cells grown to
logarithmic phase and early stationary phase using the
Qiagen DNeasy kit. DNA quality and quantity was mea-
sured using a NanoDrop 1000 spectrophotometer. To
Table 4 Overrepresented functional categories in 5-azacytidine-treated E. coli
Stage System Name p
logarithmic GOTERM_BP_FAT DNA repair 7.85E-05
logarithmic GOTERM_BP_FAT SOS response 8.10E-05
early stationary KEGG Pathway Ribosome 2.20E-10
early stationary GOTERM_CC_FAT Organelle inner membrane 7.40E-05
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assess methylation at 5′CCWGG3′ sites, DNA (0.5–
1 μg) was incubated with 10 units of the restriction en-
zymes BstNI or PspGI for 2 h at 60 °C [12]. Reactions
were monitored by electrophoresis on 1 % agarose gels
and stained with 0.5 μg/mL ethidium bromide or 1x
GelRed (VWR).
Sodium bisulfite sequencing
1 μg of DNA was treated with sodium bisulfite accord-
ing to the instructions in the EpiTect Kit (Qiagen).
Bisulfite-treated DNA was used as a template for PCR.
The conditions were 94 °C for 2 min, 94 °C for 1 min,
55 °C for 1 min, and 72 °C for 1 min for 30 cycles,
followed by one cycle of 72 °C for 10 min. Primer se-
quences are osmE-F1-D 5′GAAAAGATAAAATTTT
TTTAAAGTTAATT3′ and osmE-R1-D5′ACACT-
CAAAATTCCTACCATATTCTTATT3′. PCR products
were inserted into the pGEM-T Easy plasmid (Promega),
introduced into E. coli JM109, isolated using the alkaline
lysis procedure (Wizard SV kit, Promega), and analyzed
by Sanger sequencing (GeneWiz, New Jersey).
Total RNA Isolation
At logarithmic phase, early stationary phase, and station-
ary phase, RNA was harvested from 4 mL of cells using
the MasterPure RNA isolation kit according to the man-
ufacturer’s instructions (EpiCentre). The optional DNase
step was included in all preparations. RNA was analyzed
by spectrophotometry on a NanoDrop 1000 spectropho-
tometer. For microarray experiments, RNA quality was
assessed by bioanalysis on a RNA 6000 Nano chip at the
University of Rochester Genomics Center. RIN values
were between 8 and 10. For RT-qPCR experiments,
RNA was analyzed by bioanalysis or traditional agarose
gel electrophoresis after heating the RNA for 2 min at
65 °C in a solution containing 47.5 % formamide and
0.01 % sodium dodecyl sulfate.
DNA Microarray analysis
Microarray experiments were performed with RNA from
untreated cells and cells treated with 5 μg/mL 5-azaC. Total
RNA was treated with the reagents in the mRNA Only Pro-
karyotic mRNA Isolation Kit to reduce rRNA levels and
polyadenylate the mRNA according to the manufacturer’s
instructions (EpiCentre). Modified RNA was used as input
for array experiments. cRNA was made in the presence of
either Cy3-CTP (RNA from untreated cells) or Cy5-CTP
(RNA from 5-azaC-treated cells) using the Quick Amp 2-
color Labeling Kit (Agilent) according to the manufacturer’s
instructions. Equal amounts of dye-labeled cRNA were hy-
bridized to E. coli 8*15 K DNA microarrays arrays (Agilent
technologies). Microarrays were scanned on an Agilent
Microarray Scanner. There were five biological replicates
for both the logarithmic phase and early stationary phase
samples. Data for non E. coli K-12 genomes on the array
were removed prior to analysis. P values were determined
with one-sample t-tests. The data were considered signifi-
cant if the fold-change was > or < 2 fold and the Benjamini-
Hochberg false discovery rate (FDR) was < 0.1. Pathway
analysis was performed using DAVID with the high strin-
gency setting and the same FDR cutoff [44].
RT-qPCR analysis
RT-qPCR was performed as described previously [11].
Fold-changes were determined using the ΔΔCT method
[45]. Three or more independent samples were used for
each experiment for all targets except fimA (n = 2). The
data were considered significant if the fold change was >
or < 2-fold and the p value was <0.05 in one sample t-























DNA sequencing analysis of the rpoS promoter
PCR was used to amplify the main stationary phase specific
rpoS promoter [36, 37] and four rpoS transcription start
sites [38]. E. coli BW25113 genomic DNA was used as a
template and the Promega GoTaq master mix was used as
a source of enzyme, dNTPs, and buffer. The conditions
were 94 °C for 2 min, 94 °C for 1 min, 54 °C for 1 min, and
72 °C for 45 s for 30 cycles, followed by one cycle of 72 °C
for 10 min. The PCR products were purified using the Qia-
gen QIAquick PCR purification kit and analyzed by Sanger
DNA sequencing of both strands (GeneWiz, New Jersey).
Three forward/reverse primer pairs were utilized; rpoSp-
F1/rpoSp-R1, rpoSp-F2/rpoSp-R2, rpoSp-F3/rpoSp-R3. The
primers sequences are listed below.








All statistical tests were performed in R [46].
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